

Special Issue

Antibiotics Treatment Optimization in Vulnerable Populations

Message from the Guest Editors

Pharmacokinetic/pharmacodynamic studies allow new recommendations to be developed based on a patient's characteristics as well as clinical context and to move away from the 'one dose fits all' approach that seems to be more and more obsolete since the beginning of personalized medicine. In this Special Issue we aim to highlight new data that support new recommendations for antibiotic use to optimize care by ensuring that 'the right treatments are given to the right patient at the right dose and at the right time'. **Keywords**

- antibiotics
- pharmacokinetics
- pharmacodynamics
- dose optimization
- vulnerable populations
- personalised dosing

Guest Editors

Dr. Romain Guilhaumou

1. Service de Pharmacologie clinique et Pharmacovigilance, Hôpital de la Timone, Marseille, France 2. Aix Marseille Université, Institut de Neurosciences des Systèmes, Inserm UMR 1106, Marseille, France

Dr. Amélie Marsot

1. Laboratoire de Suivi Thérapeutique Pharmacologique et Pharmacocinétique, Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada
2. Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada

Deadline for manuscript submissions

closed (31 May 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/112177

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)